: The immunosuppressant drug cyclosporine A (CsA) has emerged as an important new cause of secondary hypertension and our previous work implicated a major neurogenic component in the pathogenesis. Using genetic mouse models, we recently showed that CsA raises blood pressure by stimulating renal sensory nerve endings containing synapsins, a family of vesicle-associated phosphoproteins that constitute putative substrates for calcineurin. In double knock out mice lacking synapsins I and II, renal sensory endings were normally developed but they were unresponsive to CsA. We now want to explore the molecular mechanism by which synapsins mediate CsA-induced renal afferent activation, and determine if targeted interruption of this novel mechanism confers protection against not only acute more importantly chronic CsA-induced hypertension. Our major new hypothesis is that calcineurin inhibition increases synapsin phosphorylation in renal sensory nerve endings, thereby accelerating exocytotic release of neurotransmiuers that act in an autocrine fashion to augment renal afferent discharge. We further hypothesize that this augmented in vivo autonomic response and the resultant hypertension are causally linked to two functionally important sites on the synapsin molecule: (1) one or more specific phosphorylation sites that constitute calcineurin substrates; and (2) the ATP binding site that is common to both synapsins. Using radiotelemetry to measure central aortic pressure in conscious unrestrained mice, our specfic aims are to determine if: (1) immunosuppressive doses of CsA produce chronic synapsin-dependent hypertension; (2) synapsin I or synapsin II is the principal isoform mediating this hypertension; (3) calcineunn is colocalized with synapsin in rena' sensory nerve endings by confocal microscopy and specific synapsiN phosphorylatiori sites constitute in vivo CsA-sensitive substrates for calcineurin in vagal nodosal ganglion neurons, (4) mutation in specific synapsin phosphorylation sites confers resistance against CsA-induced hypertension, and (5) mutation in the ATP binding site also confers resistance against CsA-induced hypertension.The distinctive features of this research include: (1) extensive phenotyping of transgenic mice to unravel a novel neural mechanism of hypertension; (2) elucidating an important role for synapsin-coated microvesicles in peripheral chemosensory transduction: and (3) providing a new conceptual framework for novel antihypertensive drug discovery to combat CsA-induced hypertension and other forms of refractory hypertension in which there is an important sympathetic component.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL044010-11A1
Application #
6546169
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Velletri, Paul A
Project Start
1990-04-01
Project End
2007-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
11
Fiscal Year
2002
Total Cost
$259,000
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Augustyniak, Robert A; Picken, Maria M; Leonard, David et al. (2010) Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: studies in sympathectomized rats. Clin Exp Pharmacol Physiol 37:12-8
Shafiq, Moiz M; Menon, Dileep V; Victor, Ronald G (2008) Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 121:265-71
Victor, Ronald G (2007) Pathophysiology of target-organ disease: does angiotensin II remain the key? J Clin Hypertens (Greenwich) 9:4-10
Augustyniak, Robert A; Victor, Ronald G; Morgan, Donald A et al. (2006) L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol 290:R726-32
Zhang, Weiguo (2002) Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc Res 53:294-303
Thomas, G D; Zhang, W; Victor, R G (2001) Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA 285:2055-7
Zhang, W; Victor, R G (2000) Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 13:999-1004
Zhang, W; Li, J L; Hosaka, M et al. (2000) Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A 97:9765-70
Zhang, W; Kowal, R C; Rusnak, F et al. (1999) Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 84:722-8
Victor, R G; Rusnak, F; Sikkink, R et al. (1997) Mechanism of Ca(2+)-dependent inactivation of L-type Ca2+ channels in GH3 cells: direct evidence against dephosphorylation by calcineurin. J Membr Biol 156:53-61

Showing the most recent 10 out of 21 publications